molecular and clinical pharmacokinetics of nnrti regimens
TRANSCRIPT
![Page 1: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/1.jpg)
Molecular and Clinical Pharmacokinetics of NNRTI
RegimensKatie Buckingham
School of Life Sciences
![Page 2: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/2.jpg)
Human Immunodeficiency Virus
• HIV-1, HIV-2
• Acquired immunodeficiency syndrome (AIDS)
• Affect >30million people worldwide
• 1.5million deaths in 2013 (WHO, 2013)
![Page 3: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/3.jpg)
Structure of HIV-1
Image source: http://www.quia.com/jg/1272861list.html
![Page 4: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/4.jpg)
The HIV life cycle
Image source: http://hivconsult.in/hiv-treatment/how-hiv-treatment-works
![Page 5: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/5.jpg)
NNRTI’s• Allosteric, non-competitive binding to the NNRTI-binding pocket
Figure2: The NNRTi Efavirenz bound to HIV-1 reverse transcriptase (Wright, DW, et al. 2012)
![Page 6: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/6.jpg)
NNRTI’s• First line regimen for HIV-1 infection• Combination therapy• Not recommended for second-line treatments
ADVANTAGES DISADVANTAGES
Lower side effects High resistance profile
Better patient compliance Cross resistance common
Long plasma half life Require strict patient adherence
![Page 7: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/7.jpg)
Current Approved NNRTI’s
Image source: Johnson BC, et al. 2012
![Page 8: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/8.jpg)
Nevirapine• Viramune© - 200mg• Bioavailability >90%• Linear kinetics at therapeutic dosing
Adverse effects• Hypersensitivity• Hepatotoxicity
Image source: avimedi.net
![Page 9: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/9.jpg)
Delavirdine• Rescriptor© - 400mg 3x daily• Bioavailabilty – 85%• T1/2 = 2.4h
Adverse effects• Anxiety, insomnia• GI and respiratory effects• Steven-Johnson’s syndrome
![Page 10: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/10.jpg)
Efavirenz• Sustiva© - 600mg• Bioavailability 40-45%• T1/2 = 52-76hrs
Adverse effects• CNS side effects – 55%• CNS toxicity – Cmin >4ng/mL• Mild rash
![Page 11: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/11.jpg)
Etravirine• Intelence© - 200mg 2x daily• Treatment experienced patients• Highly lipid soluble
Adverse effects• Rash• GI effects
![Page 12: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/12.jpg)
Rilpivirine• Edurant© - 25mg• High bioavailavility• Fasting decreases AUC and Cmax
Adverse effects• Rash• Nausea• Abnormal dreams/nightmares
![Page 13: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/13.jpg)
Drug Interactions• Unpredictable• Hepatic clearance• Metabolised by CYP450 isoenzymes• Other inhibitors/inducers of P450 enzymes
Nevirapine CYP3A4, CYP2B6 Auto-inducer
Delavirdine CYP3A4 Auto-inhibitor
Efavirenz CYP3A4, CYP2B6 Auto-inducer
Etravirine CYP3A* CYP2C9, CYP2C19 -
Rilpivirine CYP3A* -
![Page 14: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/14.jpg)
Special Populations
![Page 15: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/15.jpg)
Future Developments• Injectable formulations
-Rilpivirine-pre/post-prophylaxis-ease of use
• Novel drugs-Doravirine-Efficacy and safety-Resistance profiles
• Pharmacogenomics
![Page 16: Molecular and Clinical Pharmacokinetics of NNRTI Regimens](https://reader035.vdocument.in/reader035/viewer/2022062503/58880e321a28ab083c8b4849/html5/thumbnails/16.jpg)
Any questions?